Patent 11685750 was granted and assigned to Kymera Therapeutics on June, 2023 by the United States Patent and Trademark Office.
The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases (“IRAK”) via ubiquitination and/or degradation and uses of the same in the treatment various diseases.